Brief: Blueprint Medicines Q2 Net Income USD -49.994 Million Vs. IBES Estimate USD -80.6 Million
01/08/2024 12:01
Aug 01 (Reuters) - Blueprint Medicines Q2 operating expenses USD 181.202 million. * Q2 basic EPS USD -0.8 * Q2 EPS USD -0.8 vs. IBES estimate USD -1.29 * Q2 pretax profit USD -49.892 million vs. IBES estimate USD -80.4 million * Q2 product revenue USD 114.115 million
Recent news on Blueprint Medicines
See all newsBrief: Sanofi Announces Extension Of Blueprint Tender Offer
Brief: Blueprint Medicines Announces Data Reinforcing Safety Profile Of Long-Term Ayvakit
U.S. STOCKS ON THE MOVE-Texas Instruments, Broadcom, Circle
UBS raises Blueprint Medicines' PT on Sanofi's up to $9.5 billion takeover deal
U.S. RESEARCH ROUNDUP-Biomea Fusion, GE Aerospace, P&G